Skip to main content
main-content

Latest news stories

Latest news stories

06-18-2019 | Hypoglycemia | ADA 2019 | News

High-intensity exercise may trigger hypoglycemia counterregulatory response

Research presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, suggests that high-intensity exercise can partially restore counterregulatory responses to hypoglycemia in people with impaired awareness of the condition.

06-18-2019 | Hyperglycemia | ADA 2019 | News

Hyperglycemia may impact brain development in children with type 1 diabetes

Researchers report that having type 1 diabetes may affect children’s brain growth and cognitive development, with persistent hyperglycemia the most likely culprit.

06-14-2019 | Diabetes prevention | News

Teplizumab, low-dose ATG hold greatest type 1 diabetes immunotherapy promise

Of the immunotherapies tested to date, teplizumab and low-dose antithymocyte globulin are the most promising for slowing the decline in C-peptide in people with newly diagnosed type 1 diabetes, researchers report.

06-13-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

06-12-2019 | Canagliflozin | ADA 2019 | News

Canagliflozin benefits span multiple cardiovascular backgrounds

Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.

06-12-2019 | DPP-4 inhibitors | ADA 2019 | News

CARMELINA findings confirmed in highest CV risk subgroups

Secondary data from the CARMELINA trial, presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, confirm the positive primary cardiovascular and renal safety findings, this time in particularly high-risk patients.

06-11-2019 | Semaglutide | ADA 2019 | News

Oral semaglutide falls just short of cardioprotection in event-driven PIONEER 6

The PIONEER 6 trial demonstrates the noninferior cardiovascular safety profile of oral semaglutide compared with placebo, but fails to demonstrate superiority, despite an overall positive trend and significance for cardiovascular death.

06-11-2019 | Linagliptin | ADA 2019 | News

CAROLINA shows neutral cardiovascular profile for modern sulfonylurea

The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.

06-11-2019 | Hypoglycemia | ADA 2019 | News

CGM data can predict future severe hypoglycemia

Most hypoglycemia outcomes measured by real-time continuous glucose monitoring can be used to predict future severe hypoglycemia in people with type 1 diabetes, with similar levels of accuracy, study findings indicate.

06-11-2019 | Adolescents | ADA 2019 | News

Insulin omission for weight purposes linked to increased depression in youth

Young people who deliberately omit insulin to either lose weight or prevent weight gain report worse psychosocial functioning, particularly depressive symptoms, than those who have never skipped a dose for this reason, study data show.

06-11-2019 | Glucagon | ADA 2019 | News

Phase III data support dasiglucagon use for severe hypoglycemia

Dasiglucagon has potential as a fast, effective treatment for severe hypoglycemia in patients with type 1 diabetes, show phase III study data presented at the 79th ADA Scientific Sessions in San Francisco, California, USA.

06-11-2019 | Adolescents | ADA 2019 | News

Diabetes distress linked to self-care and HbA1c in adolescents with diabetes

Diabetes distress is more common than depression in adolescents with diabetes and is significantly associated with less frequent blood glucose monitoring and higher glycated hemoglobin levels, study findings indicate.

06-10-2019 | Dulaglutide | ADA 2019 | News

Dulaglutide cardioprotective in relatively low-risk REWIND population

The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.

06-10-2019 | Adolescents | ADA 2019 | News

Shared medical appointments improve psychosocial outcomes in young diabetes

Shared medical appointments may help adolescents with type 1 diabetes to reduce family conflict and improve their depressive symptoms, show data presented at the 79th ADA Scientific Sessions in San Francisco, California, USA.

06-10-2019 | Prediabetes | ADA 2019 | News

RISE adult medication results highlight disparity with youth with diabetes

Intensive antidiabetic treatment in adults with newly diagnosed type 2 diabetes slows the decline in beta-cell function, but this is not sustained after the treatment is stopped, show the results of the RISE adult medication study.

06-10-2019 | Semaglutide | ADA 2019 | News

PIONEER 8: Semaglutide add-on lowers HbA1c in type 2 diabetes insulin users

Oral semaglutide significantly reduces glycated hemoglobin and bodyweight versus placebo in people with type 2 diabetes that is poorly controlled on insulin, results of the PIONEER 8 study show.

06-09-2019 | Diabetes prevention | ADA 2019 | News

Teplizumab delays onset of overt type 1 diabetes

Phase II findings show that the immunotherapy teplizumab significantly prolongs the time until people at very high risk for developing type 1 diabetes are diagnosed with the condition.

06-09-2019 | SGLT2 inhibitors | ADA 2019 | News

SGLT2 inhibitor, GLP-1 receptor agonist risk–benefits explored in older adults

Older people starting treatment with sodium-glucose cotransporter 2 inhibitors have a lower risk for hospitalization for heart failure than those starting glucagon-like peptide-1 receptor agonists, research shows.

06-09-2019 | Semaglutide | ADA 2019 | News

PIONEER trials test oral semaglutide in moderate renal impairment, flexible dosing

The PIONEER 5 and 7 trials show the efficacy of oral semaglutide in people with moderate renal impairment and the potential for a flexible dosing regimen.

06-09-2019 | Type 2 diabetes | ADA 2019 | News

Short-term delays in diabetes onset confer long-term cardioprotective effects

Delaying diabetes onset by at least 6 years in people with impaired glucose tolerance significantly reduces their risk for cardiovascular disease and microvascular complications, show 30-year data from the Da Qing Diabetes Prevention Study.

Image Credits